Tumor–Antigen Activated Dendritic Cell Membrane-Coated Biomimetic Nanoparticles with Orchestrating Immune Responses Promote Therapeutic Efficacy against Glioma
ACS Nano · 14.02.2023 · 17 (3) · 2341-2355
DOI: 10.1021/acsnano.2c09033 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 23.01.2023. Verfasst von Xiaoyue Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Chongqing University, Chongqing 400044, China. Hauptthemen laut MEDLINE: Glioma, Nanoparticles. Die Arbeit wurde bisher 155-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Chongqing Science and Technology Commission, Central University Basic Research Fund of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy has had a profound positive effect on certain types of cancer but has not improved the outcomes of glioma because of the blood-brain barrier (BBB) and immunosuppressive tumor microenvironment. In this study, we developed an activated mature dendritic cell membrane (aDCM)-coated nanoplatform, rapamycin (RAPA)-loaded poly(lactic-co-glycolic acid) (PLGA), named aDCM@PLGA/RAPA, which is a simple, efficient, and individualized strategy to cross the BBB and improve the immune microenvironment precisely. In vitro cells uptake and the transwell BBB model revealed that the aDCM@PLGA/RAPA can enhance homotypic-targeting and BBB-crossing efficiently. According to the in vitro and in vivo immune response efficacy of aDCM@PLGA/RAPA, the immature dendritic cells (DCs) could be stimulated into the matured status, which leads to further activation of immune cells, such as tumor-infiltrating T cells and natural killer cells, and can induce the subsequent immune responses through direct and indirect way. The aDCM@PLGA/RAPA treatment can not only inhibit glioma growth significantly but also has favorable potential ability to induce glial differentiation in the orthotopic glioma. Moreover, the aDCM@PLGA could induce a robust CD8+ effector and therefore suppress orthotopic glioma growth in a prophylactic setup, which indicates certain tumor immunity. Overall, our work provides an effective antiglioma drug delivery system which has great potential for tumor combination immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Chongqing University, Chongqing 400044, China.
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
- Department of Biology and Biotechnology, Sapienza University of Rome, Sapienza University of Rome, Rome 00185, Italy.
ORCID-Profile: Tieying Yin, Yazhou Wang
Förderung
- Chongqing Science and Technology Commission
- Central University Basic Research Fund of China
- National Natural Science Foundation of China
Zitieren
APA
Ma, X., Kuang, L., Yin, Y., Tang, L., Zhang, Y., Fan, Q., Wang, B., Dong, Z., Wang, W., Yin, T., & Wang, Y. (2023). Tumor–Antigen Activated Dendritic Cell Membrane-Coated Biomimetic Nanoparticles with Orchestrating Immune Responses Promote Therapeutic Efficacy against Glioma. ACS Nano, 17(3), 2341-2355. https://doi.org/10.1021/acsnano.2c09033
Vancouver
Ma X, Kuang L, Yin Y, Tang L, Zhang Y, Fan Q, et al. Tumor–Antigen Activated Dendritic Cell Membrane-Coated Biomimetic Nanoparticles with Orchestrating Immune Responses Promote Therapeutic Efficacy against Glioma. ACS Nano. 2023;17(3):2341-2355. doi:10.1021/acsnano.2c09033
BibTeX
@article{Ma2023,
author = {Ma, Xiaoyue and Kuang, Lei and Yin, Ying and Tang, Lin and Zhang, Yu and Fan, Qin and Wang, Bingyi and Dong, Zhufeng and Wang, Wei and Yin, Tieying and Wang, Yazhou},
title = {Tumor–Antigen Activated Dendritic Cell Membrane-Coated Biomimetic Nanoparticles with Orchestrating Immune Responses Promote Therapeutic Efficacy against Glioma},
journal = {ACS Nano},
year = {2023},
volume = {17},
number = {3},
pages = {2341--2355},
doi = {10.1021/acsnano.2c09033}
}
EUVIMED